Empowering orthopedic surgeons with advancements that rapidly restore movement for their patients.

Are you experiencing knee problems?

Please sign up to be notified of our development progress and the initiation of our clinical study

Click here to Continue

about

Sparta is creating the first-of-its-kind synthetic cartilage platform, Galene.

The degeneration of cartilage between the joints can cause significant personal, economic, societal burden for individuals, families, and communities. In addition, acute injuries to joint cartilage can exacerbate and become debilitating over time.

We are developing cartilage-like implants so one’s life is no longer burdened by pain and immobility.

solving a massive problem that affects the world’s population
address cartilage degeneration
intersection of chemistry, mechanical engineering, biology

Leadership team

We are a team of operators, technologists, scientists, and engineers with long histories in the pharma, medtech, and nuclear arenas.

Dushyanth Surakanti
Dushyanth Surakanti
CEO
Dimitrios Angelis
Dimitrios Angelis
COO
Benjamin Wiley, PhD
Benjamin Wiley, PhD
CTO
Demetrius Siachames, PE
Demetrius Siachames, PE
Director of Engineering
Board of directors
Ken Gall, PhD
Neil S. Roth, MD
Sean Fontenot
Dimitrios Angelis
COO
Dushyanth Surakanti
CEO
Scientific Advisory Board
Adam Yanke, MD, PhD
Kristofer J. Jones, MD
Jon Dickens, MD, LTC
Brian Waterman, MD
Seth Lawrence Sherman, MD
Strategic Advisory Board
Artem Iaryguine
Artem Iaryguine
Nick Pachuda, DPM
Nick Pachuda, DPM
Strategic advisor
Kristen Moffat, PhD
Kristen Moffat, PhD

Clinical need

Knee cartilage degeneration
32.5M
Adults with osteoarthritis
16M
Annual visits as a result of knee pain
800K
Knee Cartilage repair procedures by 2030

We all have friends and family who are suffering from knee pain and limited range of motion. This is not only a problem locally, but globally. Over 500M suffer from osteoarthritis (OA). There are 16M visits in the US specifically for knee symptoms. In addition, there are hundreds of thousands osteochondral repairs per year. Unfortunately, there is a high percentage of patients who have a revision within two years. In addition, there are several million people getting a total knee replacement each year. A third of them were considered inappropriate candidates for this intervention. This issue also afflicts active military. Limited duty days exceed 1M after chondral procedures. One in three veterans have OA. The overall prevalence of knee cartilage lesions in high performance athletes is almost 40%.

our approach

We understand that behaviors and the environment can affect how one’s genes work. Furthermore, chronological age refers to the actual amount of time a person has existed, while biological age refers to epigenetic alteration and DNA methylation which express on how able and functioning a person is. The biological age of a joint is no different. Its condition is a result of prior injury, person’s daily routine, profession and diet.

Our proprietary Galene platform was developed with this reality in mind. This platform renders biological age inconsequential. Unlike cartilage regeneration technologies which take many months, if not years, to regrow strong cartilage, Galene mimics the properties of hyaline cartilage at time zero. This platform was developed at the intersection of materials science, chemistry, and engineering. Through a novel process of combining unique materials and well-known polymers, we created a bionic cartilage which replicates the tensile, compression, and wear properties in the joints of the shoulder, great toe, thumb, elbow, spine, and talus.  We modified the geometry and configuration based on the anatomical location of interest.  This allows us to more precisely and effectively address the needs of patients afflicted with osteoarthritis and cartilage defects. Our approach has the potential to provide patients with immediate pain reduction, full range of motion, resulting in a quality of life they desire.

The Ormi Circular Femoral Condyle (Ormi-CFC) implant, a Breakthrough Device, was created by combining Galene with an osseointegrative titanium base.  Ormi-CFC is intended to treat chondral and osteochondral lesions of the femoral condyle.

immediate pain reduction
+
full range of motion
=
enhanced quality of life

Clinical Benefit

A Target Product Profile (TPP) is a set of outcomes that focuses our efforts on building a solution that meaningfully improves that standard of care. Along with satisfying many safety requirements, we set a high bar on those outcomes that matter most for patients. Our TPP is unmatched by existing treatments and technologies in development. We believe this will instill confidence in surgeons as they help their patients quickly resume their daily routines and while knowing many productive years lay ahead.

Surgeons can take comfort in knowing their patients will quickly resume their routines and have highly productive lives many years to come.

Biologic / Cartilage Regeneration*
Ormi-CFC
Dependent on patient’s biology
Yes
No
Full weight bearing
Pain reduction
Several weeks
1-2 days
Achieve full range of motion
Several days/weeks
Few days
Return to biking, jogging, sports
In several weeks
Within few weeks
Durability
5 years
At least 10yrs

Pipeline

We are building a substantial pipeline of Ormí solutions. We will leverage all the know-how and preclinical testing from our knee indication and create efficient and cost effective development paths for these additional indications.

Indication
Prototype
Pre-Clinical
Clinical
body image
Femoral condyle
Unicondylar
Patella
Trochlea
OCD
CMC
MTP
Shoulder
Hip
Elbow
Talus

news

Dec 14, 2021
Sparta Biomedical Raises $5M in Series Seed Financing to Advance its Breakthrough Device for Partial Knee Resurfacing
Read more
Mar 17, 2021
Sparta Biomedical Receives FDA Breakthrough Device Designation for SBM-01 Biomimetic Implant
Read more

Resources

A Synthetic Hydrogel Composite with the Mechanical Behavior and Durability of Cartilage
A Synthetic Hydrogel Composite with the Mechanical Behavior and Durability of Cartilage
Authors: Feichen Yang, Jiacheng Zhao, William J. Koshut, John Watt, Jonathan C. Riboh, Ken Gall, Benjamin J. Wiley
Reference: Wiley Online Library (2020)
Computational and Image Processing Methods for Analysis and Automation of Anatomical Alignment and Joint Spacing in Reconstructive Surgery
Computational and Image Processing Methods for Analysis and Automation of Anatomical Alignment and Joint Spacing in Reconstructive Surgery
Authors: Usamah N. Chaudhary, Cambre N. Kelly, Benjamin R. Wesorick, Cameron M. Reese, Ken Gall, Samuel B. Adams, Guillermo Sapiro, J. Matias Di Martino
Reference: International Journal of Computer Assisted Radiology and Surgery (2022).
Functional repair of critically sized femoral defects treated with bioinspired titanium gyroid-sheet scaffolds
Functional repair of critically sized femoral defects treated with bioinspired titanium gyroid-sheet scaffolds
Authors: Cambre N. Kelly, Angela SP. Lin, Kelly EH. Leguineche, Sudhanshu Shekhar, William R. Walsh, Robert E. Guldberg, Ken Gall
Reference: Journal of the Mechanical Behavior of Biomedical Materials (2021).
High-Strength Hydrogel Attachment through Nanofibrous Reinforcement
High-Strength Hydrogel Attachment through Nanofibrous Reinforcement
Authors: Jiacheng Zhao, Alina Kirillova, Cambre N. Kelly, Heng Xu, William J. Koshut, Feichen Yang, Ken Gall, Benjamin J. Wiley
Reference: Wiley Online Library (2020).
High-strength, porous additively manufactured implants with optimized mechanical osseointegration
High-strength, porous additively manufactured implants with optimized mechanical osseointegration
Authors: Cambre N.Kelly, TianWang, JamesCrowley, DanWills, Matthew H. Pelletier, Edward R.Westrick, Samuel B.Adams, KenGall, William R.Walsh
Reference: Biomaterials. (2021).

Contact us

By clicking the button you agree to our Privacy Policy
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.